Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
7 search results for:

Inotuzumab ozogamicin 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 24-01-2018 | Leukemia | News | Article

    Venetoclax, inotuzumab ozogamicin promising in older leukemia patients

    Hepatic events and veno-occlusive disease are a known side effect of inotuzumab ozogamicin, the study authors explain, adding that 33% of participants had a grade 3–5 liver toxicity, while four patients experienced veno-occlusive disease.

    Published in:
    Lancet Oncol 2018; Advance online publication
  2. 25-08-2017 | FDA | Drug approval | Article
    approvalsWatch

    Olaparib, inotuzumab ozogamicin FDA approvals announced

    As previously reported, inotuzumab ozogamicin has been associated with severe hepatotoxicity and the prescribing information includes a boxed warning highlighting the risk of side effects including veno-occlusive disease and sinusoidal obstruction syndrome.

  3. 14-03-2018 | Article

    Advisory board comment

    Comment on: Venetoclax, inotuzumab ozogamicin promising in older leukemia patients

    Author:
    Xavier Thomas MD
  4. 08-02-2018 | Acute lymphoblastic leukemia | News | Article
    News in brief

    INO-VATE analysis demonstrates benefits for younger and older ALL patients

    Further analysis of the INO-VATE study shows that inotuzumab ozogamicin is effective across the adult acute lymphoblastic leukemia patient age range, although those aged less than 55 years may derive greater overall survival benefit.

  5. 04-08-2017 | CNS metastases | News | Article

    In other news

    In this roundup, we cover the roles of stereotactic radiosurgery in patients undergoing resection for intracranial metastases and nimotuzumab in the first-line treatment of advanced pancreatic cancer, as well as the hepatotoxicity associated with inotuzumab ozogamicin.

  6. 16-01-2018 | FDA | News | Article
    approvalsWatch

    Olaparib approved for BRCA-mutated metastatic breast cancer

    . © 2018 Springer Healthcare part of the Springer Nature group See also: Olaparib, inotuzumab ozogamicin FDA approvals announced

  7. 29-12-2016 | Lymphoma | Article

    The landscape of new drugs in lymphoma

    Most ADCs that are currently in clinical development in patients with haematological malignancies take advantage of a cleavable linker strategy, with three different types of release mechanism available within this class: firstly, lysosomal protease-sensitive linkers (brentuximab vedotin, polatuzumab vedotin); secondly, acid-sensitive linkers (inotuzumab ozogamicin); and, thirdly glutathione-sensitive linkers (anti-CD19 maytansine conjugate) 78 .

    Author:
    Anas Younes, Stephen Ansell, Nathan Fowler, Wyndham Wilson, Sven de Vos, John Seymour, Ranjana Advani, Andres Forero, Frank Morschhauser, Marie Jose Kersten, Kensei Tobinai, Pier Luigi Zinzani, Emanuele Zucca, Jeremy Abramson, Julie Vose
  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.